Cover Image
市場調查報告書

生長激素缺乏症 - 機會分析及至2024年的預測

OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026

出版商 GlobalData 商品編碼 344233
出版日期 內容資訊 英文 216 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生長激素缺乏症 - 機會分析及至2024年的預測 OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026
出版日期: 2017年05月01日 內容資訊: 英文 216 Pages
簡介

全球生長激素缺乏症市場2014年的銷售額在7大市場中成為12億6,000萬美元。預計該市場今後10年,以年複合成長率4.08%緩慢成長,2024年終達18億8,000萬美元。預計美國最快成長,預計2024年佔據全球銷售額的59%。

本報告提供生長激素缺乏症的流行病學、病因、症狀、診斷、治療指南等概要,以及治療藥市場收益、至2024年的10年預測、市場上未滿足需求、開發平台趨勢等彙整資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
  • 症狀
  • 診斷
  • 預後
  • 生活品質

第4章 流行病學

  • 背景
  • 風險因素和共生病症
  • 全球的趨勢
  • 預測方法
  • 流行病學的預測
  • 考察

第5章 競爭評估

  • 概要
  • 治療流程
  • 市場進入、償付、臨床
  • 產品簡介
    • 概要
    • 功效
    • 安全性
    • SWOT分析

第6章 未滿足需求的評估與機會分析

  • 概要
  • 改善的遵守性和適合性
  • 早期診斷
  • 日本的疾病的認識和法律規章政策
  • 帶給患者獲取影響的保險政策
  • 癌症生存者的更安全治療方法

第7章 研究開發策略

  • 概要
  • 臨床實驗設計

第8章 開發平台評估

  • 概要
  • 臨床開發的潛力藥物
  • 創新的早期方法

第9章 開發平台評估分析

  • 開發平台藥物臨床基準
  • 開發平台藥物的商業性基準
  • 競爭評估
  • 10年預測
    • 美國
    • 歐洲5國
    • 日本

第10章 附錄

圖表

目錄
Product Code: GDHC069POA

Growth hormone deficiency (GHD) is a rare endocrine disorder characterized by inadequate secretion of growth hormone (GH) from the anterior pituitary gland. It is a heterogeneous disorder that may present in childhood (pediatric GHD) or later in adult life (adult GHD). Reduced GH secretion predominantly results in stunted linear growth in children; therefore, the standard-of-care GH replacement therapy serves to normalize height in children. Adults with GHD generally demonstrate biochemical abnormalities, which can also be successfully treated with recombinant GH. GlobalData estimates the 2016 sales for GHD at approximately $1.42 billion across the 7MM covered in this report. The market will grow moderately at a CAGR of 3.9% during the 10-year forecast period, generating sales of approximately $2.08 billion at the end of 2026. The US market is expected to grow the fastest of the three regions, recording a CAGR of 4.4% and generating around 69% of global sales in 2026. This growth will be driven primarily by the highly anticipated arrivals of the long-acting GHs and the resultant increase in compliance with and adherence to therapy. Although the more convenient long-acting GHs are expected to markedly change the GHD treatment landscape, and eventually replace daily GHs, market growth will be restricted by the continued negotiations between distributers and payers, which is expected to keep the prices of these new drugs at bay.

Key Questions Answered

  • Overall, the greatest unmet need in the GHD space is the issue with treatment adherence and compliance. There are other prominent unmet needs highlighted by the Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs fulfil these unmet needs of the market?
  • The 10-year forecast period will mark the launch of four pipeline long-acting GH drugs. How will the sales of the existing drugs be impacted? Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why?
  • What are the roles of payers in this highly competitive disease space? How does this affect market shares of the GH brands? What are the chances of reimbursement for the long-acting GH drugs in pipeline?

Scope

  • Overview of GHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized GHD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GHD therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global GHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global GHD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GHD therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 7MM GHD therapeutics market from 2016-2026.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

  • Novo Nordisk
  • Pfizer
  • Genentech/Roche
  • Ipsen SA
  • Eli Lilly
  • EMD Serono
  • Ferring
  • JCR Pharmaceuticals
  • Sandoz
  • LG Life Sciences
  • Biopartners GmbH
  • OPKO Health
  • Versartis Inc.
  • Ascendis Pharma
  • Genexine Inc.
  • Hanmi Pharmaceuticals
  • Aeterna Zentaris
  • Aileron Therapeutics
  • Critical Pharmaceuticals Limited
  • Emisphere Technologies Inc.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Growth Hormone Deficiency: Executive Summary

  • 2.1. GHD Market Will Exhibit Moderate Growth Between 2016 and 2026
  • 2.2. Long-Acting Growth Hormones Will Fuel Market Growth and Improve the Treatment Landscape for GHD Patients
  • 2.3. Payer Preferences Heavily Influence Market Shares of GH Drugs in the US
  • 2.4. Disease Awareness and Stringent Regulatory and Insurance Policies Are Major Challenges in the GHD Market
  • 2.5. Opportunities for New Entrants After the Launch of Long-Acting GHs Will Be Low During the Forecast Period
  • 2.6. What Do Physicians Think?

3. Introduction

  • 3.1. Catalyst
  • 3.2. Related Reports

4. Disease Overview

  • 4.1. Etiology and Pathophysiology
    • 4.1.1. Etiology
    • 4.1.2. Pathophysiology
  • 4.2. Symptoms
  • 4.3. Prognosis
  • 4.4. Quality of Life

5. Epidemiology

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global and Historical Trends
  • 5.4. GHD in children
  • 5.5. GHD in adults
  • 5.6. Forecast Methodology
    • 5.6.1. Sources
    • 5.6.2. Forecast Assumptions and Methods
  • 5.7. Epidemiological Forecast for GHD (2016-2026)
    • 5.7.1. Diagnosed Prevalent Cases of GHD
    • 5.7.2. Age-Specific Diagnosed Prevalent Cases of GHD
    • 5.7.3. Sex-Specific Diagnosed Prevalent Cases of GHD
    • 5.7.4. Idiopathic and Organic GHD in Children
    • 5.7.5. Congenital and Acquired GHD Out of Organic GHD in Children
    • 5.7.6. Idiopathic and Acquired GHD in Adults
    • 5.7.7. Onset Timing
  • 5.8. Discussion
    • 5.8.1. Epidemiological Forecast Insight
    • 5.8.2. Limitations of Analysis
    • 5.8.3. Strengths of the Analysis

6. Current Treatment Options

  • 6.1. Overview
  • 6.2. Diagnosis and Treatment
    • 6.2.1. Diagnosis
    • 6.2.2. Treatment Guidelines and Leading Prescribed Drugs
  • 6.3. Clinical Practice
  • 6.4. Market Access and Reimbursement
  • 6.5. Product Profiles - Recombinant Human Growth Hormones
    • 6.5.1. Overview
    • 6.5.2. Genotropin
    • 6.5.3. Humatrope
    • 6.5.4. Norditropin
    • 6.5.5. Nutropin AQ
    • 6.5.6. Saizen
    • 6.5.7. Zomacton/Growject
    • 6.5.8. Omnitrope
    • 6.5.9. Valtropin Biosimilar
    • 6.5.10. Efficacy
    • 6.5.11. Safety
    • 6.5.12. SWOT Analysis
  • 6.6. Product Profiles - Long-Acting Recombinant Human Growth Hormones
    • 6.6.1. Somatropin Biopartners (LB-03002)

7. Unmet Needs and Opportunity Assessment

  • 7.1. Overview
  • 7.2. Improved Adherence to Therapy
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Disease Awareness and Physician Education
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Insurance Policies that Impact Patient Access
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Early Diagnosis
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Simpler and Safer Diagnostic Test
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Safer Treatment for Cancer Survivors
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity
  • 7.8. Improved Way of Measuring Adherence
    • 7.8.1. Unmet Need
    • 7.8.2. Gap Analysis
    • 7.8.3. Opportunity

8. R&D Strategies

  • 8.1. Overview
    • 8.1.1. Development of Long-Acting Growth Hormones
    • 8.1.2. Novel Drug Delivery Strategies
    • 8.1.3. Novel Diagnostic Methods
    • 8.1.4. Adherence-Monitoring Electronic Devices
    • 8.1.5. Licensing and Acquisitions
  • 8.2. Clinical Trials Design
    • 8.2.1. Current Clinical Trial Design
    • 8.2.2. Future Clinical Trial Design

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Somapacitan (NNC0195-0092)
    • 9.2.1. Overview
    • 9.2.2. Efficacy
    • 9.2.3. Safety
    • 9.2.4. SWOT Analysis
  • 9.3. Lagova (MOD-4023)
    • 9.3.1. Overview
    • 9.3.2. Efficacy
    • 9.3.3. Safety
    • 9.3.4. SWOT Analysis
  • 9.4. Somavaratan (VRS-317)
    • 9.4.1. Overview
    • 9.4.2. Efficacy
    • 9.4.3. Safety
    • 9.4.4. SWOT Analysis
  • 9.5. TransCon Growth Hormone (ACP-001)
    • 9.5.1. Overview
    • 9.5.2. Efficacy
    • 9.5.3. Safety
    • 9.5.4. SWOT Analysis
  • 9.6. Innovative Early-Stage Approaches

10. Pipeline Valuation Analysis

  • 10.1. Clinical Benchmark of Key Pipeline Drugs
  • 10.2. Commercial Benchmark of Key Pipeline Drugs
  • 10.3. Competitive Assessment
  • 10.4. Top-Line 10-Year Forecast
    • 10.4.1. US
    • 10.4.2. 5EU
    • 10.4.3. Japan

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
    • 11.3.1. Forecasting Methodology
    • 11.3.2. Diagnosed Patients
    • 11.3.3. Percent Drug-Treated Patients
    • 11.3.4. Drugs Included in Each Therapeutic Class
    • 11.3.5. Launch and Patent Expiry Dates
    • 11.3.6. General Pricing Assumptions
    • 11.3.7. Individual Drug Assumptions
    • 11.3.8. Pricing of Pipeline Agents
  • 11.4. Primary Research - KOLs Interviewed for This Report
  • 11.5. Payers Included in This Study
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Managing Epidemiologist
    • 11.7.5. Global Director of Therapy Analysis and Epidemiology
    • 11.7.6. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Contact Us
  • 11.10. Disclaimer
Back to Top